| The HER2-low revolution in breast oncology: steps forward and emerging challenges E Nicolò, L Boscolo Bielo, G Curigliano, P Tarantino Therapeutic Advances in Medical Oncology 15, 17588359231152842, 2023 | 39 | 2023 |
| Variant allele frequency: a decision-making tool in precision oncology? LB Bielo, D Trapani, M Repetto, E Crimini, C Valenza, C Belli, ... Trends in Cancer 9 (12), 1058-1068, 2023 | 32 | 2023 |
| Targeting cellular components of the tumor microenvironment in solid malignancies C Belli, G Antonarelli, M Repetto, L Boscolo Bielo, E Crimini, G Curigliano Cancers 14 (17), 4278, 2022 | 21 | 2022 |
| Molecular tumour board at European Institute of Oncology: report of the first three year activity of an Italian precision oncology experience M Repetto, E Crimini, LB Bielo, E Guerini-Rocco, L Ascione, A Bonfanti, ... European Journal of Cancer 183, 79-89, 2023 | 15 | 2023 |
| The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 M Repetto, E Crimini, L Ascione, L Boscolo Bielo, C Belli, G Curigliano Investigational new drugs 40 (5), 1133-1136, 2022 | 12 | 2022 |
| Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis … C Valenza, D Trapani, S Gandini, C Sposetti, LB Bielo, A Marra, ... European Journal of Cancer 190, 112944, 2023 | 8 | 2023 |
| Future potential targets of antibody-drug conjugates in breast cancer C Corti, LB Bielo, AC Schianca, BT Salimbeni, C Criscitiello, G Curigliano The Breast 69, 312-322, 2023 | 8 | 2023 |
| Antibody-drug conjugates in breast cancer: what is beyond HER2? E Nicolò, M Repetto, LB Bielo, P Tarantino, G Curigliano The Cancer Journal 28 (6), 436-445, 2022 | 8 | 2022 |
| Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer L Cantini, D Trapani, L Guidi, LB Bielo, R Scafetta, M Koziej, L Vidal, ... Cancer Treatment Reviews 123, 102669, 2024 | 7 | 2024 |
| The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer LB Bielo, D Trapani, E Nicolò, C Valenza, L Guidi, C Belli, E Kotteas, ... Cancer Treatment Reviews, 102761, 2024 | 6 | 2024 |
| Postneoadjuvant treatment for triple-negative breast cancer D Trapani, E Ferraro, F Giugliano, LB Bielo, G Curigliano, HJ Burstein Current Opinion in Oncology 34 (6), 623-634, 2022 | 5 | 2022 |
| Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild-type metastatic … D Ciardiello, LB Bielo, S Napolitano, E Martinelli, T Troiani, A Nicastro, ... Annals of Oncology 35 (12), 1105-1115, 2024 | 4 | 2024 |
| Deleterious alterations in homologous recombination repair genes and efficacy of platinum-based chemotherapy in biliary tract cancers C Belli, L Boscolo Bielo, M Repetto, E Crimini, R Scalia, A Diana, ... The Oncologist, oyae125, 2024 | 3 | 2024 |
| Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel Antibody-Drug Conjugates S Natangelo, D Trapani, C Koukoutzeli, LB Bielo, G Marvaso, ... Critical Reviews in Oncology/Hematology, 104270, 2024 | 3 | 2024 |
| Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer B Taurelli Salimbeni, E Ferraro, L Boscolo Bielo, G Curigliano Breast Cancer Research and Treatment: Innovative Concepts, 237-281, 2024 | 2 | 2024 |
| Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents E Nicolò, P Tarantino, O D’Ecclesiis, G Antonarelli, L Boscolo Bielo, ... The Oncologist 29 (1), 75-83, 2024 | 2 | 2024 |
| Treatment optimization in early triple negative breast cancer E Kotteas, L Boscolo Bielo, C Valenza, C Santoro, C Koukoutzeli, ... Expert review of anticancer therapy 23 (10), 1107-1116, 2023 | 2 | 2023 |
| Pharmacoeconomics of novel pharmacotherapies in triple-negative breast cancer L Boscolo Bielo, D Trapani, G Curigliano Expert Opinion on Pharmacotherapy 24 (7), 789-801, 2023 | 2 | 2023 |
| Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact K Venetis, C Frascarelli, LB Bielo, G Cursano, R Adorisio, M Ivanova, ... European Journal of Cancer, 115233, 2025 | 1 | 2025 |
| Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations LB Bielo, EG Rocco, D Trapani, P Zagami, BT Salimbeni, A Esposito, ... ESMO open 9 (10), 103731, 2024 | 1 | 2024 |
